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To appreciate the involvement of known or potential 
susceptibility genes in sporadic breast tumors, we have 
searched for chromosomal deletions by studying loss of 
heterozygosity (LOH) at 43 microsatellite (CA)1 
markers from human chromosomes 10, 11 and 17, in 
115 unselected consecutive samples of breast carcinoma 
with particular emphasis on specific regions. No site of 
consistent LOH was identified on chromosome 10. Five 
regions of LOH were contained within bands q22-24 of 
chromosome 11 for which nearly 50% of the tumors had 
LOH at at least one marker. This region is thus a major 
site of deletion in breast cancer and several tumor 
suppressor genes seem to be involved. One of them may 
be the ataxia telangiectasia (A TM) gene which is located 
in one of the affected regions. Five regions of LOH, one 
of which is within the BRCA1  gene area, were 
recognized along chromosome 17. LOH at three of 
these regions were found in highly proliferative tumors. 
When combined with a previous study of chromosome 13 
with emphasis on BRCA2  and R b l  genes, this work 
allowed to distinguish a total of 12 regions of LOH, 
variably affected in breast tumors and correlated with 
prognostic parameters.
t
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Introduction
Mutations in tumor suppressor genes seem iinportant 
in the development of familial and so-called sporadic 
breast carcinomas. Several chromosome sites, suspected 
or known to contain such genes, are involved, often in 
the same tumor. Sites of potential alterations have been 
identified by studying losses of chromosomal segments 
or by genetic linkage analysis in cancer prone families. 
Major regions of loss of heterozygosity (LOH) 
correspond to the location of known cancer genes, 
such as TP53 on the short arm of chromosome 17 and 
E-cadherin on chromosome arm 16q, or of putative 
tumor suppressor genes that have not been character­
ized yet. Segments of genome frequently deleted in
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breast tumors and suspected to contain tumor 
suppressor genes are on chromosome arms lp, lq, 
3p, 6q, 7q, 8p, l ip ,  11 q, 13q, I 6q, 17p, 17q, 18q and 
22q (reviewed in Devilee and Cornelisse, 1994 and 
Bieche and Lidereau, 1995). Linkage and mutation 
analyses have identified the B R C A I  and BRCA2  genes, 
located on the long arm of chromosome 17 and 13 
respectively, as major loci for hereditary breast cancer 
(Stzatton and Wooster, 1996, for review).
In addition to B R C A I  and B R C A 2 , other loci, while 
being involved in breast cancer susceptibility, could 
also play a role in the development o f sporadic breast 
tumors. Increased susceptibility to breast cancer has 
been noted in carriers of constitutional translocations 
involving the llq23  band (Lindblom et al,, 1994). The 
possible involvement of the recently isolated (Savitsky 
et al., 1995) ataxia-telangiectasia (A T M )  gene, located 
at llq22~23, in breast cancer susceptibility has been 
suggested (Swift et al., 1987). The importance of 
putative loci from chromosome region llq22-23 in 
sporadic breast cancer, suspected after cytogenetic 
studies (Feri-Passantonopoulou et al., 1991; Hains- 
worth et a l 1991), has been recently revealed by LOH 
analysis (Carter et a l 1994; H am pton et al., 1994a; 
Koreth et a l , 1995; Windqvist et al., 1995). Breast 
tumors are also frequently observed in patients with 
Cowden disease (Starink et ciL, 1986), The gene for this 
syndrome has been mapped to chromosome region
10q22-23 (Nelen et a l ,  1996).
We have looked for LOH at chromosome 10, 1 i and 
17, with special emphasis on regions hosting known or 
putative breast tumor susceptibility genes, i.e. 10q22- 
23, llq22~24 and 17q-12-21. We have cumulated this 
analysis with a previous study of chromosome 13 
where the B R C A 2  gene is located, in order to evalaute 
the possible role in sporadic tumors of genomic regions 
which contain loci with either proven or potential 
involvement in mammary carcinogenesis and possible 
interactions between them. In addition, we have 
attempted a combined quantitative analysis of 12 
defined regions of LOH with respect to histo-clinical 
parameters.
Results
For each chromosome, the largest number of 
microsatellites was chosen within or close to the
r ,v >x
p - y í
340
Sporadic breast cancer and susceptibility gene regions
F Kerangueven et al
regions of interest, i.e. 10q22-23, llq22-24 and 17ql2- 
21 to estimate the incidence of LOH. The other 
markers were used for comparison, to determine if 
this incidence was prominent for the given chromo­
some or if other regions exhibited LOH at a 
comparable or different frequency. The number of 
tumor samples tested varied from 67 to 115 depending 
on the marker.
L O H  at markers fro m  chromosome 10
Fourteen microsatellite markers were used to search for 
LOH at chromosome arms lOp and lOq. Six of them, 
from D10S201 to D10S185, are closely linked in a 15 cM 
interval (Gyapay et al., 1994; Dib et al., 1996; Moshonas 
et al., 1996) in the recently defined Cowden disease 
region, at 10q22-23. In linkage analyses (Nelen et a l , 
1996), the maximum lod score was obtained with marker 
D10S573 and the most probable location of the diesease 
gene was defined between D10S215 and D10S564. 
Markers D10S532 and D10S541, which in our hands, 
gave better informativity, were used instead of D10S573 
and D10S215, respectively (Gyapay et a l , 1994).
Figure 1 presents a summary of the LOH results on 
this chromosome. Taking into account only informative 
cases, the percentage of LOH at each marker ranged 
from 13-27%  (Figure 1). Overall, this incidence was 
close to the general background we observed in previous 
studies (Kerangueven et a l , 1995a,b,c). LOH at markers 
from the Cowden region varied from 16 -23% , not 
above the average incidence noted all along the 
chromosome. Half o f  this was due to monosomies but 
some interstitial deletions were observed. However, they 
were distributed over the two arms and no precise region 
of consistent loss could be identified.
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Figure 1 Schematic representation of the distribution of LOH at 
chromosome 10 in representative breast carcinomas. At left is a 
diagram of chromosome 10, with the location of the microsatellite 
(CA)n markers and genes potentially involved in tumorigenesis, as 
known to date. Numbers at far right represent the ratio of tumors 
with LOH vs the informative cases (the total number of analysed 
tumors varied from 48 to 115, depending on the marker)
The previous results provide evidence against the 
involvement of Cowden disease region in sporadic 
breast cancer. To further investigate the possible 
participation of chromosome region 10q22-23 in breast 
carcinogenesis, this time in genetic predisposition to 
breast cancer, and in other conditions than the Cowden 
disease itself, we set up a linkage analysis of breast 
cancer families. Seven families with breast cancer only 
syndrome, previously selected on the basis of absence of 
linkage to BRCA1  and BRCA2  linkage (Kerangueven et 
a/., 1995b) were tested with markers D 10S201 , D10S532 
and D10S541 as described (Kerangueven et a l , 1995b). 
Total cumulative lod scores were negative at several 
values of 0 (not shown). Lod scores were weakly 
positive (0.20) for D10S201 at 6>0.2 but this was 
dependent on one family only. Even if a lod score of - 2  
(hypothesis of independence) was not reached, the 
results are not in favor of the hypothesis of the 
Cowden disease gene being a BRCA  gene.
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Figure 2 Illustration of LOH at chromosome ll markers. 
Computer representation of the polyacrylamide gel analysis by 
automatic sequencing apparatus of polymerase chain reaction 
products from selected tumors (lower rows) and corresponding 
blood samples (upper rows). The microsatellite alleles are 
represented by two (heterozygote) peaks except in the case of 
homozygosity (non informative cases). LOH at one allele (arrows) 
corresponds to a significant decrease in one of the two peaks. The 
higher molecular weight allele is on the left in each tracing
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LOH at markers from chromosome 11
A total of 19 markers from chromosome 11 were studied. 
Figure 2 shows representative LOH and Figure 3 presents 
a summary of the results obtained in the 1 lq22-24 region. 
Taking into account only informative cases, the 
percentages of LOH at each marker ranged from 24- 
26% at D 11S901 and D 11S917, to 41 -  51 % at D 11S1356, 
D11S528 and D11S910 (Figure 3). In contrast, LOH at 
markers from chromosome arm l ip  did not exceed the 
20% range (not shown) which, as previously mentioned 
above for chromosome 10 markers, correspond in our 
hands to a background of sporadic losses which does not 
allow the identification of a particular region (Keran­
gueven et al., 1995a,b,c). The incidence of 50% is in close 
agreement with findings by other groups (Carter et a l , 
1994; Hampton et a l ., 1994b; Koreth et a l , 1995).
The tumor samples could be separated into two 
distinct groups, according to their pattern of LOH. In 
a first group of tumors, LOH was observed at all 
chromosome arm l lq  markers, suggesting that 
inactivation of one allele of a putative tumor 
suppressor gene could have occurred in these tumors 
by large deletion or, in a few cases distinguished by 
LOH at chromosome arm l ip  markers as well, by 
processes resulting in monosomy. A second group (as 
detailed in Figure 3) comprised tumors with LOH 
detected with only a restricted number of l lq  markers, 
i.e. with interstitial deletions.
Five regions of consistent loss, designated a to e, all 
located in bands llq22-24 (Van Heyningen and Little,
1995), were identified. They were centered on markers 
D11S1818 in the A T M  gene area, D11S940 just 
centromeric, and D11S1356, D11S925 and D11S934, 
telomeric to ATM. Regions were defined on the basis of 
involvement of several tumors showing LOH and 
retention of heterozygosity at adjacent markers. For 
example, in Figure 3, tumors 1288, 5809 and 5411 are 
used to define region a, tumors 5411, 5510 and 5362 to 
define region e. The distance between these regions is 
still important, and this certainly calls for a refined 
study. Importantly, region b contains the A T M  locus, 
defined by markers D11S1343 to D11S2106 (Savitsky et 
a l , 1995).
LOH at markers from chromosome 17
Ten markers from chromosome 17 were studied to search 
for LOH at both arms, with emphasis on the BRCA1  gene 
region, at 17q2L Representative results are shown in 
Figure 4 and summarized in Figure 5. Five regions of 
LOH, two on 17p, three on 17q, were individualized. One 
region of 17q, deleted in almost half of the tumor samples, 
was located within or near the BRCA1 gene area. 
Incidence of LOH in region e was low and identification 
of this region could have been neglected, since as it was 
mentioned for chromosome 10 markers, it was close to the 
background value, It was only legitimized by the existence
1Mb |
ATM H
ETS1 
FLI1 ^
D11S901 —
D11S919 
D11S917 —
D11S940
D11S1343
i m
181347
D11S1356
D11S523
D11S925
D11S1S2S
D11S934 —
D11S910
D11S969
a
d
e
15/62 (24%)
25/62 (40%)
b 34/70 (49%) 
31/67 (46%)
40/88 (45%)
36/70 (51%) 
32/78 (41%)
16/42 (38%) 
38/78 (49%)
27/58 (47%)
Figure 3 Schematic representation of the distribution of LOH at chromosome arm llq  in human breast tumors, At far left is a 
diagram of a portion of chromosome arm llq , with the location of the microsatellite (CA)n markers as it is known to date (Gyapay 
ct c i l 1994; Van Heyningen and Little, 1995). The middle panel is a schematization of allelic losses in representative lumois of the 
panel. Black lanes indicate LOH; absence of black lane means that the region is unaffected. Numbers at far right represent the ratio 
of tumors with LOH vs the informative cases (the total number of analysed tumors was 115) for the selected maikeis (in the A T M  
region, numbers correspond to D11S1818 and D11S2106). Vertical bars on the right indicate common regions of minimal loss. 
Tumors with an amplification of genes from the llq l3  band are designated with a black square on top
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of several tumors (541 i, 1062, 5743 and 5510 in Figures 4 
and 5) with a pattern of LOH in thè distai portion of 
chromosome arm 17q.
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Figure 4 Illustration of LOH at chromosome 17 markers. See 
also legend of Figure 2
Cumulative regional allelotyping
Even if some tumors presented interstitial deletions 
with markers of chromosome 10, the Cowden disease 
area, or any other portion of chromosome 10, was not 
considered as a major region of consistent loss. Our 
LOH analysis of three chromosomes with 43 markers 
thus allowed to define 10 regions affected in breast 
tumors on chromosomes 11 and 17. A previous study 
of chromosome 13 with eight markers, allowed us to 
identify two additional regions of LOH, possibly 
associated with BRCA2  and R bl  genes, respectively 
(Kerangueven et a l , 1995a).
We looked for correlations between clinico-patho- 
logical parameters and LOH at a given region, and 
performed a combined analysis on all 12 regions from 
chromosomes 10, 11, 13 and 17. This analysis, 
designated ‘cumulative regional allelotyping’ (CRA), 
puts emphasis on quantitative data (Kerangueven et 
al, 1996). The scoring of regions of LOH was done 
on 31 tumors tested with all markers (including 
chromosome 13 markers) as follows: scoring was 
done on two contiguous markers per defined region;, 
a region was positive if LOH occurred at at least one 
marker, negative if the two alleles were present for 
each marker, or if one of the marker was non 
informative and the other has retained heterozygos­
ity; the region was non informative in a given tumor if 
the two markers were non informative (accordingly, 
the proportion of tumors affected for each region 
varies slightly from the proportion affected for each 
marker).
CRA on a total of 12 regions of LOH distributed 
over the four chromosomes provided information 
(shown in Figures 6 and 7) on both the distribution 
of affected regions per tumor, and the proportion of 
affected tumors per region of LOH.
The proportion of affected tumors (31 = 100% of 
LOH) varied according to the region considered 
(Figures 6 and 7). No region presented less than 30% 
or more than 60% of LOH (Figure 6a). Two regions 
were deleted in the 30-40%  range, as shown in 
Figures 6a and 7. The other 10 regions were affected 
in more than 40% of the cases. LOH at a given region 
of a chromosome arm was independent of LOH at
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Figure 5 Schematic representation of the distribution of LOH at chromosome 17 in representative breast carcinomas. At far left is a 
diagram of chromosome 17, with the location of the microsatellite (CA)n markers and of tumor suppressor genes, as known to date. The 
middle panel is a schematization of allelic losses in tumors of the panel. Results are represented as follows: open squares, r e te n t io n  of 
heterozygosity; black squares, LOH; gray squares, non informative; nd, no data. Numbers at far right represent the ratio of tumors w ith  
LOH vs the informative cases. Vertical bars on the right indicate five regions of minimal loss
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Figure 6 Cumulative analysis of LOH in a panel of 31 breast carcinomas with LOH at 51 markers from chromosomes 10, 11, 13 
and 17*. respective distributions of affected regions and tumors. A. number of affected regions of consistent loss as a function of 
tumors (31 = 100%). B. number of affected tumors as a function of regions (15 = 100%)
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Figure 7 Cumulative regional allelotyping of chromosomes 10, 11, 13 and 17. Relative frequencies (in %) of LOH at 15 regions 
(this presentation has correspondence in 6a). As indicated below, regions can be classified in three classes according to frequency of 
involvement. No region is involved in less than 30 and more than 60% of tumors
other regions of the same arm and independent of 
LOH on a different arm or chromosome except in a 
few cases. LOH at regions 17b and 17c (P = 0.013), at 
13a and 13b (P = 0.0001), and two regions from 
different chromosomes, such as 11a and 17d 
(P = 0.005) were significantly associated.
When specific regions were considered, the propor­
tions of LOH were as follows: the A T M  gene region 
was involved in 48% of tumors, the BRCA1 gene 
region in 48% and the BRCA2  gene region in 52%. 
These figures for the three regions are strikingly close
and may represent a maximum of incidence for a given 
gene.
The proportion of affected regions (12=100% of 
LOH) varied from tumor to tumor. Every tumor but 
three presented LOH at at least one region. Twelve 
tumors presented LOH at one, two or three regions 
only. Fourteen tumors showed LOH at more than 60% 
of the regions (Figure 6b). This distribution showed 
clearly the existence of two groups of tumors, one with 
a low level of LOH (0 to 30%, in Figure 6b) and one 
with a high level of LOH (from 40 to more than 90%). 
The tumors with a low level of LOH were character- 
ized by a lower mitotic index (P = 0.017). These two 
groups of tumors may be caused by different molecular 
alterations and may have distinct clinical evolutions. If
344
Sporadic breast cancer and susceptibility gene regions
F Kerangueven et al
this turns out to be the case, this type of cumulative 
analysis would be particularly helpful in assessing the 
initial prognosis.
Correlation with clinico-histo logical parameters
A statistical analysis of the correlations between LOH 
and clinico-pathological parameters was performed.
Among the 31 tumors, the ones with LOH at 13a 
(BRCA2  region) were associated with the presence of 
metastatic lymph nodes (P ~  0.007) and with an age 
below 50 (£ = 0.015). Tumors with LOH at regions 
17a, 17b (P53 region) and 17c were highly prolif­
erative. LOH at regions 1 7 a -c  was indeed correlated 
with a high grade, due to a high mitotic index 
(P = 0.02 to 0.005). However, LOH at region 17d 
(BRCA1) was not significantly correlated with high 
grade, although we have observed a similar correlation 
between high mitotic index and BRCA1  gene germ 
line mutations (Eisinger et al., 1996). It is possible 
that different mechanisms of BRCA1  inactivation lead 
to tumors with distinct clinico-pathological para­
meters.
With respect to l l q  markers, no strong correlation 
with any of the parameters was evidenced. Winqvist et 
al. (1995) found that LOH at 11 q23 is predictive of 
aggressive postmetastatic course. Clinical follow-up of 
tumors from our panels will be done to assess this 
point. Amplification of the llq l3 -14  region has been 
detected in 15-25%  of breast carcinomas (Gaudray et 
al., 1992). Such a process may alter the structure of 
chromosome arm l l q  and lead to the loss of the 
remaining portion of the chromosome, creating LOH 
which could be falsely interpreted as the inactivation of 
a tumor suppressor gene. Upon examination of cases 
with both types of alteration (Figure 3), LOH at llq23 
did not seem to be associated with amplification (as 
tested by Southern blot hybridization with several 
probes from 1 l q l 3 band -not shown) since loci 
telomeric of 1 l q l 3 (D11S919, D11S917) are retained 
in most cases. Furthermore, the possibility that the 
l lq l3  band contains a tumor suppressor gene has been 
evoked (Zhuang et a l ,  1995) but was not apparent in 
our study. The same was true for chromosome arm 17q 
and ERBB2  amplification.
Discussion
Our first goal was to determine regions of LOH on 
specific chromosomes, i.e. chromosomes 10, Î1 and 17, 
in breast tumors. In prostate cancer, LOH at 10q22-24, 
in a region slightly telomeric of the Cowden locus, has 
been evidenced (Gray et a l 1995; Ittman, 1996) and 
the role of P A C 1 , on 10pter-qll, and M ix l  at 10q25, 
two potential tumor suppressor genes, has been 
investigated (Gray et aL, 1995; Sanchez et al., 1996). 
However, in breast cancer, no evidence for the 
participation of genes from chromosome 10 could be 
obtained from the LOH data.
LOH at markers of chromosome region llq22-23 
has been observed in several types of cancer, including 
bladder (Shaw and Knowles, 1995), cervical (Hampton 
et al., 1994b; Bethwaite et a l , 1995) colorectal 
(Keldysh et al., 1993), lung (Iizuka et al., 1995), 
nasopharyngeal (Hui et al., 1996), ovarian (Foulkes et
a l 1993; Davis et a l,  1996; Gabra et al., 1996) and 
stomach (Baffa et a l ,  1996) carcinomas, and in 
melanomas (Tomlinson et a l,  1993; Herbst et al
1995), and thus may host at least one so-called 
multiple tumor suppressor gene, the activity of which 
is not restricted to breast epithelial cells. Further 
studies will aim at refining the localization of this 
important locus. Unfortunately, because of the 
variability in the choice of the markers studied, it is 
difficult to determine if the l lq  regions of most 
frequent LOH are the same in the different types of 
tumors. A survey of the various reports (also 
summarized in Davis et al., 1996 and in Hui et a l ,
1996) indicates that regions d and e reported here 
could be identical to two regions of LOH observed in 
ovarian cancers (Davis et a l , 1996; Gabra et al., 1996) 
while regions b and d, which have already been 
evidenced in breast cancer by other authors (Negrini 
et al., 1995) are apparently also affected in bladder 
(Shaw and Knowles, 1995), cervical (Hampton et al., 
1994a), lung (Rasio et a l , 1995), nasopharyngeal (Hui 
et a l, 1996) and ovarian (Gabra et al., 1996) cancers. 
Alternatively, the llq22-23 region may contain several 
tumor suppressor genes variably involved in different 
types of cancer. There are several potential candidates. 
Since the A T M  gene has been suspected to play a role 
in cancer susceptibility (Swift et a l,  1987), its 
participation may be suspected. The involvement of 
the M LL/A LL1  gene (Rowley, 1993) located close to 
D1 IS 1356 (Van Heyningen and Little, 1995) and 
which has been found to be deleted in a gastric 
carcinoma cell line (Baffa et al., 1995), or of 
unidentified tumor suppressor genes, potentially also 
involved in familial cases (Lindblom et a l , 1994; 
Sobol et a l, 1994), should also be investigated. One of 
the putative tumor suppressor genes may be a 
metastasis suppressor gene (Phillips et a l, 1996). The 
zebra pattern observed in this area is intriguing and 
needs further investigation with additional markers to 
obtain a better definition of the affected regions. In 
addition to being due to several potential tumor 
suppressor genes, special instability in the region may 
be responsible for the complexity of the LOH pattern.
Five regions of loss, two of them on 17pl2-13, have 
been identified by several authors in breast carcinomas 
and other cancers (Cropp et a l,  1993; Kirchweger et 
al., 1994; Nagai et a l, 1995; Schultz et a l,  1996) and 
coarsely correspond to the ones defined here.
Our second goal was to determine whether the 
region containing known or putative breast tumor 
susceptibility genes were affected by LOH in sporadic 
tumors. This question has already been evoked and 
partly answered with respect to BRCA1  and BRCA2  
gene regions (Cleton-Jansen et a l, 1995; Cropp et al, 
1993; Kerangueven et a l, 1995a; Kirchweger et al, 
1994; Nagai et a l, 1995). For the Cowden disease 
region, the low frequency of LOH and the absence of 
linkage to familial breast tumors both suggest that it is 
not prominently involved in cancer. However, it 
remains possible that the gene is involved in sporadic 
breast cancer by other ways than deletion. Our study 
of Cowden disease region in seven hereditary breast 
cancer families did not provide evidence for linkage, 
but it remains very preliminary and needs to be 
strengthened by an extensive study with more families 
and more markers.
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We also provided evidence for the possible 
involvement of the ataxia telangiectasia region in 
breast tumorigenesis. However, other regions with 
similar or greater frequency could be identified 
nearby, and it is by no means certain that the gene 
involved in ataxia telangiectasia is the same as the 
one(s) involved in breast carcinogenesis. Finding so 
many sites of deletion in this region remains intriguing. 
It is possible that not all sites correspond to a bona fide 
tumor suppressor gene and that some deletions are due 
to an overall greater instability of the region.
The third goal was to stress on the fact that a large 
number of genomic regions may host tumor suppressor 
genes involved in breast cancer and to suggest a way to 
analyse cumulative quantitative data. In contrast, our 
goal was not directed towards the refinement of 
identified regions, something that may be better 
performed on concentrating efforts on selected sites.
Materials and methods
Tumor samples
One hundred and fifteen unselected primary breast 
carcinomas, and blood samples from the same patients, 
were collected at Institut Paoli-Calmettes in Marseille (48 
tumors) and Institut Paul Lamarque in Montpellier (67 
tumors). The following clinical and biological parameters 
were studied in this panel: tumor size, histoprognostic 
grade, lymph node (N) status (47% and 41% of N positive 
tumors, for the two panels, respectively), hormonal 
receptors (63% and 68% of estrogen receptor positive, 
53% and 68% progesterone receptor positive), DNA index 
(70%) with aneuploidy), S-phase, ERBB2, and p53 status. 
Genomic DNAs were extracted as previously described 
(Theillet et al., 1989).
Genetic markers analysis
DNAs were examined for LOH with the following 
microsateliites (CA)n markers oriented according to recent 
consensus maps (Gyapay et al., 1994; Matise et al., 1994; 
Van Heyningen and Little, 1995; Dib et a l 1996; 
Moshonas et a l 1996): Chromsome 10: D10S558, 
DIOS 191, D10S199, D10S561, D10S201, D10S532,
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